Review



pyromark mgmt kit investigating cpgs 74 78  (Pyrosequencing Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Pyrosequencing Inc pyromark mgmt kit investigating cpgs 74 78
    Flowchart of patient selection. MGMTpm, <t>MGMT</t> promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR
    Pyromark Mgmt Kit Investigating Cpgs 74 78, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyromark mgmt kit investigating cpgs 74 78/product/Pyrosequencing Inc
    Average 86 stars, based on 1 article reviews
    pyromark mgmt kit investigating cpgs 74 78 - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing"

    Article Title: MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing

    Journal: Journal of Neuro-Oncology

    doi: 10.1007/s11060-026-05633-0

    Flowchart of patient selection. MGMTpm, MGMT promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR
    Figure Legend Snippet: Flowchart of patient selection. MGMTpm, MGMT promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR

    Techniques Used: Selection, Methylation

    MGMT promoter methylation status and cut-offs. ( a ) Distribution of mean MGMTpm status of all 451 patients. The solid green line representing the supervised cut-off ( b ) and the dashed black line representing the unsupervised cut-off ( c ). Distributions for each individual CpG are presented in Supplementary Fig. . ( b ) Cut-off supervised by OS and adjusted for prognostic factors: age, extent of resection and preoperative ECOG performance status (solid green line), determined through 5-fold cross-validation with the highest concordance index corresponding to the best performing AFT (accelerated failure time) model. ( c ) Bimodal normal mixture model, with unsupervised cut-off (dashed black line) determined as the intersection point of the two distributions. Blue bars represent patients with methylated MGMT and red bars represent patients with unmethylated MGMT, according to the supervised cut-off (solid green line, b )
    Figure Legend Snippet: MGMT promoter methylation status and cut-offs. ( a ) Distribution of mean MGMTpm status of all 451 patients. The solid green line representing the supervised cut-off ( b ) and the dashed black line representing the unsupervised cut-off ( c ). Distributions for each individual CpG are presented in Supplementary Fig. . ( b ) Cut-off supervised by OS and adjusted for prognostic factors: age, extent of resection and preoperative ECOG performance status (solid green line), determined through 5-fold cross-validation with the highest concordance index corresponding to the best performing AFT (accelerated failure time) model. ( c ) Bimodal normal mixture model, with unsupervised cut-off (dashed black line) determined as the intersection point of the two distributions. Blue bars represent patients with methylated MGMT and red bars represent patients with unmethylated MGMT, according to the supervised cut-off (solid green line, b )

    Techniques Used: Methylation, Biomarker Discovery



    Similar Products

    pyromark mgmt kit investigating cpgs 74 78  (Pyrosequencing Inc)
    86
    Pyrosequencing Inc pyromark mgmt kit investigating cpgs 74 78
    Flowchart of patient selection. MGMTpm, <t>MGMT</t> promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR
    Pyromark Mgmt Kit Investigating Cpgs 74 78, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pyromark mgmt kit investigating cpgs 74 78/product/Pyrosequencing Inc
    Average 86 stars, based on 1 article reviews
    pyromark mgmt kit investigating cpgs 74 78 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Flowchart of patient selection. MGMTpm, MGMT promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR

    Journal: Journal of Neuro-Oncology

    Article Title: MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing

    doi: 10.1007/s11060-026-05633-0

    Figure Lengend Snippet: Flowchart of patient selection. MGMTpm, MGMT promoter methylation; RT, radiotherapy; TMZ, Temozolomide. * Meningioma, ependymoma, diffuse midline glioma, pilocytic astrocytoma, ganglioglioma, fibrillary astrocytoma, oligodendroglioma IDHmut, gemistocytic astrocytoma IDHmut and germinoma ** Including patients not receiving postoperative treatment. *** preopPS, or extent of resection **** thereby absent from the SQR

    Article Snippet: A third option is to establish a cut-off based on outcome, such as in the study by Quillien where the Pyromark MGMT kit investigating CpGs 74–78 in exon 1 of the MGMT gene by pyrosequencing was used and a cut-off of ≥ 9% for mMGMT was proposed [ ].

    Techniques: Selection, Methylation

    MGMT promoter methylation status and cut-offs. ( a ) Distribution of mean MGMTpm status of all 451 patients. The solid green line representing the supervised cut-off ( b ) and the dashed black line representing the unsupervised cut-off ( c ). Distributions for each individual CpG are presented in Supplementary Fig. . ( b ) Cut-off supervised by OS and adjusted for prognostic factors: age, extent of resection and preoperative ECOG performance status (solid green line), determined through 5-fold cross-validation with the highest concordance index corresponding to the best performing AFT (accelerated failure time) model. ( c ) Bimodal normal mixture model, with unsupervised cut-off (dashed black line) determined as the intersection point of the two distributions. Blue bars represent patients with methylated MGMT and red bars represent patients with unmethylated MGMT, according to the supervised cut-off (solid green line, b )

    Journal: Journal of Neuro-Oncology

    Article Title: MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing

    doi: 10.1007/s11060-026-05633-0

    Figure Lengend Snippet: MGMT promoter methylation status and cut-offs. ( a ) Distribution of mean MGMTpm status of all 451 patients. The solid green line representing the supervised cut-off ( b ) and the dashed black line representing the unsupervised cut-off ( c ). Distributions for each individual CpG are presented in Supplementary Fig. . ( b ) Cut-off supervised by OS and adjusted for prognostic factors: age, extent of resection and preoperative ECOG performance status (solid green line), determined through 5-fold cross-validation with the highest concordance index corresponding to the best performing AFT (accelerated failure time) model. ( c ) Bimodal normal mixture model, with unsupervised cut-off (dashed black line) determined as the intersection point of the two distributions. Blue bars represent patients with methylated MGMT and red bars represent patients with unmethylated MGMT, according to the supervised cut-off (solid green line, b )

    Article Snippet: A third option is to establish a cut-off based on outcome, such as in the study by Quillien where the Pyromark MGMT kit investigating CpGs 74–78 in exon 1 of the MGMT gene by pyrosequencing was used and a cut-off of ≥ 9% for mMGMT was proposed [ ].

    Techniques: Methylation, Biomarker Discovery